<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.cancernetwork.com/view/who-benefits-most-from-perioperative-therapy-in-high-risk-prostate-cancer-</loc><lastmod>2026-11-16T21:00:00Z</lastmod><news:news><news:publication_date>2026-11-16T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Who Benefits Most From Perioperative Therapy in High-Risk Prostate Cancer?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/darovasertib-plus-crizotinib-yields-21-1-month-os-in-first-line-uveal-melanoma</loc><lastmod>2026-11-16T19:00:00Z</lastmod><news:news><news:publication_date>2026-11-16T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Darovasertib Plus Crizotinib Yields 21.1-Month OS in First-Line Uveal Melanoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/rocbrutinib-plus-r-chop-yields-high-complete-response-rate-in-non-gcb-dlbcl</loc><lastmod>2026-11-16T18:00:00Z</lastmod><news:news><news:publication_date>2026-11-16T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Rocbrutinib Plus R-CHOP Yields High Complete Response Rate in Non-GCB DLBCL]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/belzutifan-plus-lenvatinib-earns-positive-chmp-opinion-in-advanced-ccrcc</loc><lastmod>2026-11-16T16:00:00Z</lastmod><news:news><news:publication_date>2026-11-16T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Belzutifan Plus Lenvatinib Earns Positive CHMP Opinion in Advanced ccRCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/cretostimogene-cuts-recurrence-risk-in-intermediate-risk-high-grade-ta-nmibc</loc><lastmod>2026-11-16T15:30:00Z</lastmod><news:news><news:publication_date>2026-11-16T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Cretostimogene Cuts Recurrence Risk in Intermediate-Risk, High-Grade Ta NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-approves-pertuzumab-biosimilar-in-her2-breast-cancer</loc><lastmod>2026-11-16T15:00:14.845Z</lastmod><news:news><news:publication_date>2026-11-16T15:00:14.845Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Pertuzumab Biosimilar in HER2+ Breast Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/remote-monitoring-strategies-for-crs-during-outpatient-bispecific-therapy</loc><lastmod>2026-11-16T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-16T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Remote Monitoring Strategies for CRS During Outpatient Bispecific Therapy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/first-line-options-for-non-clear-cell-rcc</loc><lastmod>2026-11-16T13:05:00Z</lastmod><news:news><news:publication_date>2026-11-16T13:05:00Z</news:publication_date>
        <news:title><![CDATA[First-Line Options for Non–Clear Cell RCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-proves-crl-to-ivonescimab-chemotherapy-for-pretreated-egfr-nsclc</loc><lastmod>2026-11-16T13:02:15.089Z</lastmod><news:news><news:publication_date>2026-11-16T13:02:15.089Z</news:publication_date>
        <news:title><![CDATA[FDA Provides CRL to Ivonescimab/Chemotherapy for Pretreated EGFR+ NSCLC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/counseling-patients-with-brain-metastases-in-rcc</loc><lastmod>2026-11-16T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Counseling Patients With Brain Metastases in RCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/hematology-oncology-fellowship-in-the-golden-era-of-cancer-research</loc><lastmod>2026-11-16T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Hematology Oncology Fellowship in The “Golden Era” of Cancer Research]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/unmet-needs-and-practice-changing-takeaways</loc><lastmod>2026-11-16T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Unmet Needs and Practice-Changing Takeaways]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/partnering-with-local-hospitals-to-manage-crs-and-icans-from-bispecific-antibodies</loc><lastmod>2026-11-15T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-15T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/matching-neoadjuvant-therapy-to-tumor-genomics-in-high-risk-prostate-cancer</loc><lastmod>2026-11-15T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-15T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/subsequent-therapy-may-have-narrowed-the-overall-survival-gap-in-litespark-011</loc><lastmod>2026-11-14T17:00:00Z</lastmod><news:news><news:publication_date>2026-11-14T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/managing-emergencies-during-outpatient-bispecific-step-up-dosing</loc><lastmod>2026-11-14T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-14T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Managing Emergencies During Outpatient Bispecific Step-Up Dosing]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/can-ai-fix-clinical-trial-access-in-oncology-dr-arturo-loaiza-bonilla-built-the-answer-with-the-data-to-back-it-</loc><lastmod>2026-11-14T00:00:00Z</lastmod><news:news><news:publication_date>2026-11-14T00:00:00Z</news:publication_date>
        <news:title><![CDATA[Can AI Fix Clinical Trial Access in Oncology? Dr. Arturo Loaiza-Bonilla Built the Answer With the Data to Back It.]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/prizlon-cel-earns-fda-rmat-and-fast-track-designations-in-relapsed-lbcl</loc><lastmod>2026-11-13T23:00:00Z</lastmod><news:news><news:publication_date>2026-11-13T23:00:00Z</news:publication_date>
        <news:title><![CDATA[Prizlon-cel Earns FDA RMAT and Fast Track Designations in Relapsed LBCL]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/why-caregivers-are-critical-during-bispecific-step-up-dosing</loc><lastmod>2026-11-13T21:00:00Z</lastmod><news:news><news:publication_date>2026-11-13T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Why Caregivers Are Critical During Bispecific Step-Up Dosing]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/managing-belzutifan-toxicity-and-shared-decision-making-in-adjuvant-rcc</loc><lastmod>2026-11-13T20:55:00Z</lastmod><news:news><news:publication_date>2026-11-13T20:55:00Z</news:publication_date>
        <news:title><![CDATA[Managing Belzutifan Toxicity and Shared Decision-Making in Adjuvant RCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/litespark-022-immature-overall-survival-data-and-the-added-toxicity-trade-off</loc><lastmod>2026-11-13T20:52:00Z</lastmod><news:news><news:publication_date>2026-11-13T20:52:00Z</news:publication_date>
        <news:title><![CDATA[LITESPARK-022: Immature Overall Survival Data and the Added-Toxicity Trade-Off]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/choosing-between-regimens-and-what-s-coming-next-in-the-adc-pipeline</loc><lastmod>2026-11-13T19:30:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:30:00Z</news:publication_date>
        <news:title><![CDATA[Choosing Between Regimens — and What’s Coming Next in the ADC Pipeline]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/rosella-and-keynote-b96-two-new-standards-head-to-head-on-design-and-data</loc><lastmod>2026-11-13T19:26:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:26:00Z</news:publication_date>
        <news:title><![CDATA[ROSELLA and KEYNOTE-B96: Two New Standards, Head-to-Head on Design and Data]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/litespark-022-trial-design-and-the-dfs-benefit-in-adjuvant-rcc</loc><lastmod>2026-11-13T19:24:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:24:00Z</news:publication_date>
        <news:title><![CDATA[LITESPARK-022 Trial Design and the DFS Benefit in Adjuvant RCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/platinum-resistant-ovarian-cancer-the-problem-and-the-current-standard-of-care</loc><lastmod>2026-11-13T19:24:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:24:00Z</news:publication_date>
        <news:title><![CDATA[Platinum-Resistant Ovarian Cancer: The Problem and the Current Standard of Care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/what-makes-serena-6-compelling-quality-of-life-ctdna-clearance-and-the-pada-1-heritage</loc><lastmod>2026-11-13T19:08:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:08:00Z</news:publication_date>
        <news:title><![CDATA[What Makes SERENA-6 Compelling: Quality of Life, ctDNA Clearance, and the PADA-1 Heritage]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/the-serena-6-design-switching-therapy-before-the-scan-changes</loc><lastmod>2026-11-13T19:07:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:07:00Z</news:publication_date>
        <news:title><![CDATA[The SERENA-6 Design: Switching Therapy Before the Scan Changes]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/managing-patient-expectations-and-the-oncology-access-gap</loc><lastmod>2026-11-13T19:07:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:07:00Z</news:publication_date>
        <news:title><![CDATA[Managing Patient Expectations and the Oncology Access Gap]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/destiny-breast11-t-dxd-moves-into-the-neoadjuvant-her2-positive-setting</loc><lastmod>2026-11-13T19:06:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:06:00Z</news:publication_date>
        <news:title><![CDATA[DESTINY-Breast11: T-DXd Moves Into the Neoadjuvant HER2-Positive Setting]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/reading-pipeline-data-in-real-time-hype-promise-and-single-arm-phase-2-trials</loc><lastmod>2026-11-13T19:05:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:05:00Z</news:publication_date>
        <news:title><![CDATA[Reading Pipeline Data in Real Time: Hype, Promise, and Single-Arm Phase 2 Trials]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/the-nivopostop-controversy-open-label-design-a-negative-central-read-and-the-keynote-689-comparison</loc><lastmod>2026-11-13T19:05:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:05:00Z</news:publication_date>
        <news:title><![CDATA[The NIVOPOSTOP Controversy: Open-Label Design, a Negative Central Read, and the KEYNOTE-689 Comparison]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/the-biomarker-era-mrd-ctdna-and-treatment-de-escalation-across-tumor-types</loc><lastmod>2026-11-13T19:04:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:04:00Z</news:publication_date>
        <news:title><![CDATA[The Biomarker Era: MRD, ctDNA, and Treatment De-Escalation Across Tumor Types]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/nivopostop-adjuvant-nivolumab-after-surgery-in-high-risk-locally-advanced-head-and-neck-cancer</loc><lastmod>2026-11-13T19:04:00Z</lastmod><news:news><news:publication_date>2026-11-13T19:04:00Z</news:publication_date>
        <news:title><![CDATA[NIVOPOSTOP: Adjuvant Nivolumab After Surgery in High-Risk Locally Advanced Head and Neck Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-approves-perioperative-durvalumab-enfortumab-vedotin-in-mibc</loc><lastmod>2026-11-13T18:47:09.365Z</lastmod><news:news><news:publication_date>2026-11-13T18:47:09.365Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/trotabresib-plus-crt-fails-to-improve-pfs-in-newly-diagnosed-glioblastoma</loc><lastmod>2026-11-13T17:00:11.708Z</lastmod><news:news><news:publication_date>2026-11-13T17:00:11.708Z</news:publication_date>
        <news:title><![CDATA[Trotabresib Plus CRT Fails to Improve PFS in Newly Diagnosed Glioblastoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/the-open-questions-no-crossover-sequencing-resistance-and-where-serds-fit</loc><lastmod>2026-11-13T16:19:00Z</lastmod><news:news><news:publication_date>2026-11-13T16:19:00Z</news:publication_date>
        <news:title><![CDATA[The Open Questions: No Crossover, Sequencing, Resistance, and Where SERDs Fit]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/acs-updates-prostate-cancer-screening-guideline-with-risk-based-psa-intervals</loc><lastmod>2026-11-13T16:00:00Z</lastmod><news:news><news:publication_date>2026-11-13T16:00:00Z</news:publication_date>
        <news:title><![CDATA[ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/rems-certification-and-team-wide-training-for-bispecific-administration-in-multiple-myeloma</loc><lastmod>2026-11-13T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-13T15:00:00Z</news:publication_date>
        <news:title><![CDATA[REMS Certification and Team-Wide Training for Bispecific Administration in Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/frontline-io-tki-therapy-for-symptomatic-bulky-metastatic-rcc</loc><lastmod>2026-11-13T13:05:00Z</lastmod><news:news><news:publication_date>2026-11-13T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Frontline IO-TKI Therapy for Symptomatic, Bulky Metastatic RCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/optimal-cytoreduction-and-early-trial-referral-in-high-risk-newly-diagnosed-myeloma</loc><lastmod>2026-11-13T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-13T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Optimal Cytoreduction and Early Trial Referral in High-Risk Newly Diagnosed Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/second-line-options-and-selecting-ipilimumab-plus-nivolumab-in-rcc</loc><lastmod>2026-11-13T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-13T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Second-Line Options and Selecting Ipilimumab Plus Nivolumab in RCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/what-sustained-mrd-negativity-can-settle-about-stopping-myeloma-maintenance</loc><lastmod>2026-11-12T21:00:00Z</lastmod><news:news><news:publication_date>2026-11-12T21:00:00Z</news:publication_date>
        <news:title><![CDATA[What Sustained MRD Negativity Can Settle About Stopping Myeloma Maintenance]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/managing-hypoxia-anemia-and-cardiac-toxicity-with-belzutifan-plus-lenvatinib</loc><lastmod>2026-11-12T19:00:00Z</lastmod><news:news><news:publication_date>2026-11-12T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Managing Hypoxia, Anemia, and Cardiac Toxicity With Belzutifan Plus Lenvatinib]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/survival-in-childhood-and-adolescent-cancers-improves-but-racial-disparities-persist</loc><lastmod>2026-11-12T17:00:00Z</lastmod><news:news><news:publication_date>2026-11-12T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Survival in Childhood and Adolescent Cancers Improves, but Racial Disparities Persist]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/anthracycline-chemo-may-accelerate-biological-aging-in-breast-cancer-survivors</loc><lastmod>2026-11-12T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-12T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/contextualizing-mrd-negativity-and-pfs-across-treatment-regimens-in-relapsed-refractory-multiple-myeloma</loc><lastmod>2026-11-12T13:05:00Z</lastmod><news:news><news:publication_date>2026-11-12T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Contextualizing MRD Negativity and PFS Across Treatment Regimens in Relapsed/Refractory Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/ascent-03-sacituzumab-govitecan-versus-chemotherapy-in-first-line-metastatic-tnbc</loc><lastmod>2026-11-12T13:05:00Z</lastmod><news:news><news:publication_date>2026-11-12T13:05:00Z</news:publication_date>
        <news:title><![CDATA[ASCENT-03: Sacituzumab Govitecan Versus Chemotherapy in First-Line Metastatic TNBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/celmods-with-car-t-cell-therapy-and-bispecific-antibodies-in-multiple-myeloma</loc><lastmod>2026-11-12T13:05:00Z</lastmod><news:news><news:publication_date>2026-11-12T13:05:00Z</news:publication_date>
        <news:title><![CDATA[CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/excaliber-rrmm-trial-results-mrd-negativity-and-progression-free-survival-in-relapsed-refractory-multiple-myeloma</loc><lastmod>2026-11-12T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-12T13:00:00Z</news:publication_date>
        <news:title><![CDATA[EXCALIBER-RRMM Trial Results: MRD Negativity and Progression-Free Survival in Relapsed/Refractory Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/how-should-belzutifan-plus-lenvatinib-fit-into-advanced-rcc-sequencing-</loc><lastmod>2026-11-12T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-12T13:00:00Z</news:publication_date>
        <news:title><![CDATA[How Should Belzutifan Plus Lenvatinib Fit Into Advanced RCC Sequencing?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/celmods-as-holding-and-bridging-therapy-in-multiple-myeloma</loc><lastmod>2026-11-12T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-12T13:00:00Z</news:publication_date>
        <news:title><![CDATA[CELMoDs as Holding and Bridging Therapy in Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/tropion-breast02-expert-perspectives-on-efficacy-clinical-applicability-and-representation-in-metastatic-tnbc</loc><lastmod>2026-11-12T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-12T13:00:00Z</news:publication_date>
        <news:title><![CDATA[TROPION-Breast02: Expert Perspectives on Efficacy, Clinical Applicability, and Representation in Metastatic TNBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/real-world-teclistamab-shows-deep-responses-in-r-r-multiple-myeloma-cohort</loc><lastmod>2026-11-11T20:00:00Z</lastmod><news:news><news:publication_date>2026-11-11T20:00:00Z</news:publication_date>
        <news:title><![CDATA[Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/arteraai-prostate-test-added-to-nccn-guidelines-for-bcr-after-prostatectomy</loc><lastmod>2026-11-11T18:00:00Z</lastmod><news:news><news:publication_date>2026-11-11T18:00:00Z</news:publication_date>
        <news:title><![CDATA[ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/video-aided-informed-consent-enhances-patient-education-in-gastric-cancer-surgery</loc><lastmod>2026-11-11T17:00:12.418Z</lastmod><news:news><news:publication_date>2026-11-11T17:00:12.418Z</news:publication_date>
        <news:title><![CDATA[Video-Aided Informed Consent Enhances Patient Education in Gastric Cancer Surgery]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/virtuoso-robotic-system-earns-fda-de-novo-nod-for-en-bloc-bladder-resection</loc><lastmod>2026-11-11T16:00:00Z</lastmod><news:news><news:publication_date>2026-11-11T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/identifying-which-patients-with-hcc-need-immunotherapy-before-liver-transplant</loc><lastmod>2026-11-11T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-11T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Identifying Which Patients With HCC Need Immunotherapy Before Liver Transplant]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/adding-pembrolizumab-to-sbrt-does-not-improve-efs-in-early-stage-nsclc</loc><lastmod>2026-11-11T14:00:00Z</lastmod><news:news><news:publication_date>2026-11-11T14:00:00Z</news:publication_date>
        <news:title><![CDATA[Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/acylfulvene-prodrug-lp-184-shows-tolerability-in-recurrent-glioblastoma</loc><lastmod>2026-11-10T21:00:00Z</lastmod><news:news><news:publication_date>2026-11-10T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-accepts-snda-for-gedatolisib-in-pik3ca-mutant-hr-her2-breast-cancer</loc><lastmod>2026-11-10T20:00:00Z</lastmod><news:news><news:publication_date>2026-11-10T20:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutant HR+/HER2– Breast Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-approves-pimicotinib-for-tenosynovial-giant-cell-tumor</loc><lastmod>2026-11-10T18:00:17.011Z</lastmod><news:news><news:publication_date>2026-11-10T18:00:17.011Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/hyperthermic-mitomycin-c-yields-68-1-year-hg-rfs-in-bcg-unresponsive-nmibc</loc><lastmod>2026-11-10T18:00:00Z</lastmod><news:news><news:publication_date>2026-11-10T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/european-commission-expands-melflufen-label-to-third-line-multiple-myeloma</loc><lastmod>2026-11-10T17:30:00Z</lastmod><news:news><news:publication_date>2026-11-10T17:30:00Z</news:publication_date>
        <news:title><![CDATA[European Commission Expands Melflufen Label to Third-Line Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-approves-oncomate-msi-dx-as-pembrolizumab-companion-diagnostic-in-msi-h-solid-tumors</loc><lastmod>2026-11-10T17:00:00Z</lastmod><news:news><news:publication_date>2026-11-10T17:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/silevertinib-shows-robust-cns-activity-in-egfr-mutated-nsclc-trial</loc><lastmod>2026-11-10T16:00:00Z</lastmod><news:news><news:publication_date>2026-11-10T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Silevertinib Shows Robust CNS Activity in EGFR-Mutated NSCLC Trial]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-rejects-application-for-ttfields-in-brain-metastases-from-nsclc</loc><lastmod>2026-11-10T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-10T15:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Rejects Application for TTFields in Brain Metastases From NSCLC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/what-can-the-us-and-japan-learn-from-each-other-on-liver-cancer-prevention-</loc><lastmod>2026-11-10T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-10T13:00:00Z</news:publication_date>
        <news:title><![CDATA[What Can the US and Japan Learn From Each Other on Liver Cancer Prevention?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/nogapendekin-alfa-bcg-earns-israeli-approval-in-bcg-unresponsive-nmibc</loc><lastmod>2026-11-09T22:00:00Z</lastmod><news:news><news:publication_date>2026-11-09T22:00:00Z</news:publication_date>
        <news:title><![CDATA[Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/evolving-perioperative-treatment-landscape-for-resectable-gastric-and-gastroesophageal-junction-cancers-a-q-a-with-dr-nataliya-uboha</loc><lastmod>2026-11-09T20:23:28.937Z</lastmod><news:news><news:publication_date>2026-11-09T20:23:28.937Z</news:publication_date>
        <news:title><![CDATA[Evolving Perioperative Treatment Landscape for Resectable Gastric and Gastroesophageal Junction Cancers: A Q&A with Dr Nataliya Uboha]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/comparing-liver-cancer-prevention-strategies-in-japan-and-the-us</loc><lastmod>2026-11-09T20:00:00Z</lastmod><news:news><news:publication_date>2026-11-09T20:00:00Z</news:publication_date>
        <news:title><![CDATA[Comparing Liver Cancer Prevention Strategies in Japan and the US]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/top-3-poster-takeaways-in-liver-cancer-care-from-the-liver-meeting-2026</loc><lastmod>2026-11-09T19:00:00Z</lastmod><news:news><news:publication_date>2026-11-09T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Top 3 Poster Takeaways in Liver Cancer Care From The Liver Meeting 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/pasritamig-plus-jnj-9401-yields-73-psa-response-in-metastatic-crpc</loc><lastmod>2026-11-09T17:00:00Z</lastmod><news:news><news:publication_date>2026-11-09T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/cesalatamig-monotherapy-yields-responses-in-pd--l-1-resistant-nsclc</loc><lastmod>2026-11-09T16:00:00Z</lastmod><news:news><news:publication_date>2026-11-09T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/piktor-plus-paclitaxel-yields-responses-in-pretreated-pam-mutated-endometrial-cancer</loc><lastmod>2026-11-09T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-09T15:00:00Z</news:publication_date>
        <news:title><![CDATA[PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/managing-dermatologic-toxicity-and-holding-therapy</loc><lastmod>2026-11-09T13:05:00Z</lastmod><news:news><news:publication_date>2026-11-09T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Managing Dermatologic Toxicity and Holding Therapy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/bone-metastases-prognosis-and-treatment-selection</loc><lastmod>2026-11-09T13:05:00Z</lastmod><news:news><news:publication_date>2026-11-09T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Bone Metastases, Prognosis, and Treatment Selection]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/subcutaneous-dosing-and-supporting-adherence-at-home</loc><lastmod>2026-11-09T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-09T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Subcutaneous Dosing and Supporting Adherence at Home]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/ketamine-for-depression-in-cancer-separating-real-promise-from-hype</loc><lastmod>2026-11-09T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-09T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Ketamine for Depression in Cancer: Separating Real Promise From Hype]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/how-metastatic-sites-shape-first-line-urgency</loc><lastmod>2026-11-09T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-09T13:00:00Z</news:publication_date>
        <news:title><![CDATA[How Metastatic Sites Shape First-Line Urgency]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/azacitidine-plus-ruxolitinib-shows-durable-responses-in-myelofibrosis</loc><lastmod>2026-11-08T17:00:00Z</lastmod><news:news><news:publication_date>2026-11-08T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/defining-the-optimal-window-for-cytoreductive-sabr-in-metastatic-kidney-cancer</loc><lastmod>2026-11-08T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-08T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/closing-the-hcc-surveillance-gap-in-masld-without-cirrhosis</loc><lastmod>2026-11-08T00:00:00Z</lastmod><news:news><news:publication_date>2026-11-08T00:00:00Z</news:publication_date>
        <news:title><![CDATA[Closing the HCC Surveillance Gap in MASLD Without Cirrhosis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/weighing-hcc-surveillance-for-patients-with-masld-and-f3-fibrosis</loc><lastmod>2026-11-07T22:00:00Z</lastmod><news:news><news:publication_date>2026-11-07T22:00:00Z</news:publication_date>
        <news:title><![CDATA[Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/closing-the-gap-between-tumor-board-recommendations-and-liver-cancer-care</loc><lastmod>2026-11-07T21:00:00Z</lastmod><news:news><news:publication_date>2026-11-07T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/rethinking-surveillance-and-multidisciplinary-care-in-masld-related-hcc</loc><lastmod>2026-11-07T20:00:00Z</lastmod><news:news><news:publication_date>2026-11-07T20:00:00Z</news:publication_date>
        <news:title><![CDATA[Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/building-systems-to-catch-liver-and-other-cancers-in-patients-with-masld</loc><lastmod>2026-11-07T18:00:00Z</lastmod><news:news><news:publication_date>2026-11-07T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Building Systems to Catch Liver and Other Cancers in Patients With MASLD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/eliciting-patient-preferences-to-guide-hcc-treatment-decisions</loc><lastmod>2026-11-07T16:00:00Z</lastmod><news:news><news:publication_date>2026-11-07T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Eliciting Patient Preferences to Guide HCC Treatment Decisions]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/changing-mindsets-and-removing-guilt-surrounding-lung-cancer-diagnoses</loc><lastmod>2026-11-07T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-07T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Changing Mindsets and Removing Guilt Surrounding Lung Cancer Diagnoses]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/rusfertide-improves-hematocrit-control-vs-placebo-in-polycythemia-vera</loc><lastmod>2026-11-07T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-07T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/what-separates-a-next-generation-liver-tumor-board-from-the-traditional-model-</loc><lastmod>2026-11-07T02:00:00Z</lastmod><news:news><news:publication_date>2026-11-07T02:00:00Z</news:publication_date>
        <news:title><![CDATA[What Separates a Next-Generation Liver Tumor Board From the Traditional Model?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/weighing-immunotherapy-for-bridging-and-downstaging-before-hcc-transplant</loc><lastmod>2026-11-07T00:00:00Z</lastmod><news:news><news:publication_date>2026-11-07T00:00:00Z</news:publication_date>
        <news:title><![CDATA[Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/how-should-liver-function-and-patient-values-guide-hcc-treatment-</loc><lastmod>2026-11-06T22:00:00Z</lastmod><news:news><news:publication_date>2026-11-06T22:00:00Z</news:publication_date>
        <news:title><![CDATA[How Should Liver Function and Patient Values Guide HCC Treatment?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/masld-raises-liver-and-other-cancer-risks-supporting-selective-hcc-surveillance</loc><lastmod>2026-11-06T20:00:00Z</lastmod><news:news><news:publication_date>2026-11-06T20:00:00Z</news:publication_date>
        <news:title><![CDATA[MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/bot-bal-yields-long-term-survival-in-patients-with-refractory-mss-mcrc</loc><lastmod>2026-11-06T16:30:00Z</lastmod><news:news><news:publication_date>2026-11-06T16:30:00Z</news:publication_date>
        <news:title><![CDATA[BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/tambiciclib-combo-shows-activity-in-relapsed-refractory-post-venetoclax-aml</loc><lastmod>2026-11-06T16:00:00Z</lastmod><news:news><news:publication_date>2026-11-06T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/training-invasiveness-and-workload-behind-falling-prostate-brachytherapy-use</loc><lastmod>2026-11-06T15:00:00Z</lastmod><news:news><news:publication_date>2026-11-06T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Training, Invasiveness, and Workload Behind Falling Prostate Brachytherapy Use]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/interpreting-lenvatinib-plus-pembrolizumab-data-in-frontline-rcc</loc><lastmod>2026-11-06T14:58:00Z</lastmod><news:news><news:publication_date>2026-11-06T14:58:00Z</news:publication_date>
        <news:title><![CDATA[Interpreting Lenvatinib Plus Pembrolizumab Data in Frontline RCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/patient-factors-guiding-frontline-regimen-selection-in-advanced-rcc</loc><lastmod>2026-11-06T14:55:00Z</lastmod><news:news><news:publication_date>2026-11-06T14:55:00Z</news:publication_date>
        <news:title><![CDATA[Patient Factors Guiding Frontline Regimen Selection in Advanced RCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/young-adults-with-lung-cancer-often-fall-outside-screening-guidelines</loc><lastmod>2026-11-06T13:00:00Z</lastmod><news:news><news:publication_date>2026-11-06T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Young Adults With Lung Cancer Often Fall Outside Screening Guidelines]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-approves-sc-amivantamab-for-recurrent-metastatic-hnscc</loc><lastmod>2026-11-05T23:38:00.818Z</lastmod><news:news><news:publication_date>2026-11-05T23:38:00.818Z</news:publication_date>
        <news:title><![CDATA[FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url></urlset>